Hye-Sol Jung
Overview
Explore the profile of Hye-Sol Jung including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
45
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Yun W, Kim D, Lee M, Han Y, Chae Y, Jung H, et al.
BMC Cancer
. 2024 Aug;
24(1):1048.
PMID: 39187784
Background: Pancreatic cancer is anatomically divided into pancreatic head and body/tail cancers, and some studies have reported differences in prognosis. However, whether this discrepancy is induced from the difference of...
12.
Kim H, Huh S, Park J, Han Y, Ahn K, Noh Y, et al.
Mol Cell Proteomics
. 2024 Aug;
23(9):100824.
PMID: 39097268
Pancreatic ductal adenocarcinoma (PDAC) suffers from a lack of an effective diagnostic method, which hampers improvement in patient survival. Carbohydrate antigen 19-9 (CA19-9) is the only FDA-approved blood biomarker for...
13.
Jung H, Kwon W, Yun W, Paik W, Lee S, Ryu J, et al.
J Hepatobiliary Pancreat Sci
. 2024 Jul;
31(10):737-746.
PMID: 39034526
Background: Neoadjuvant treatment (NAT) is standard for borderline resectable pancreatic cancer (BRPC). However, consensus is lacking on the optimal surgical timing for patients with BRPC undergoing NAT. The aim of...
14.
Yun W, Han Y, Jung H, Kwon W, Park J, Jang J
J Hepatobiliary Pancreat Sci
. 2024 Jul;
31(9):601-610.
PMID: 39020260
Background: Approximately 50% of pancreatic cancer cases are diagnosed with distant metastases, commonly in the liver, leading to poor prognosis. With modern chemotherapy regimens extending patient survival and stabilizing metastasis,...
15.
Lee M, Chae Y, Park S, Yun W, Jung H, Han Y, et al.
J Hepatobiliary Pancreat Sci
. 2024 Jul;
31(9):671-679.
PMID: 39004799
Background: Advances in chemotherapy have led to increasing major vascular resection during pancreatectomy which has been contraindicated due to high morbidity. This study aimed to verify the safety and oncological...
16.
Kazmi S, Jung H, Han Y, Yun W, Cho Y, Lee M, et al.
Pancreatology
. 2024 Mar;
24(3):463-488.
PMID: 38480047
Background: The management of branch-duct type intraductal papillary mucinous neoplasms (BD-IPMN) varies in existing guidelines. This study investigated the optimal surveillance protocol and safe discontinuation of surveillance considering natural history...
17.
Jung H, Han Y, Yun W, Cho Y, Lee M, Lee D, et al.
Int J Surg
. 2024 Feb;
110(5):2883-2893.
PMID: 38376856
Introduction: The applicability of neoadjuvant treatment (NAT) for resectable pancreatic ductal adenocarcinoma (PDAC) has arisen, however, high-level evidence is lacking. This study aimed to explore patient subgroups with high-risk resectable...
18.
Optimal Surveillance Interval of Branch Duct Intraductal Papillary Mucinous Neoplasm of the Pancreas
Han Y, Kwon W, Lee M, Jung H, Yun W, Cho Y, et al.
JAMA Surg
. 2024 Jan;
159(4):389-396.
PMID: 38231494
Importance: Despite the increasing prevalence of intraductal papillary mucinous neoplasm (IPMN), data on the growth and malignant conversion rates based on long-term surveillance cohorts are limited. Many international guidelines recommend...
19.
Jung H, Lee M, Han Y, Thomas A, Yun W, Cho Y, et al.
HPB (Oxford)
. 2023 Dec;
26(3):400-409.
PMID: 38114399
Background: Invasive carcinomas arising from premalignant lesions are currently staged by the same criteria as conventional pancreatic ductal adenocarcinoma. Methods: Clinicopathologic information and survival data were extracted through a thorough...
20.
Yun W, Han Y, Cho Y, Jung H, Lee M, Kwon W, et al.
Ann Surg Oncol
. 2023 Nov;
31(2):1336-1346.
PMID: 37991581
Background: In this era of increasing neoadjuvant chemotherapy, methods for evaluating responses to neoadjuvant chemotherapy are still diverse among institutions. Additionally, the efficacy of adjuvant chemotherapy for patients undergoing neoadjuvant...